| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Pfizer protects $6.4bn heart disease blockbuster from generics, for now | ||
| Mi | Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact | ||
| Mi | Novartis' Q1 sales miss hints at industry's utilisation of M&A remedies | ||
| Mi | Arcera and Fosun sign MoU for neuroscience innovation | ||
| Mi | Rocket to sell PRV for $180m to advance gene therapy pipeline | ||
| Di | Merck KGaA and Remepy join forces to develop combo drug-digital therapies | ||
| Di | Seaport and Hemab target $180m IPOs as biotech listings accumulate | ||
| Di | BioMarin acquires Amicus Therapeutics for $4.8bn | ||
| Di | FDA approves AstraZeneca's Saphnelo for SLE | ||
| Mo | Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics | ||
| Mo | Novartis secures pair of regulatory wins for skin disease and malaria treatments | ||
| Mo | UK biotech could be bound for recovery, BIA report reveals | ||
| Mo | Sun Pharma to acquire Organon for $11.75bn | ||
| Fr | Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings | ||
| Fr | OZMOSI and Planview partner to enhance pharmaceutical data integration | ||
| Fr | Regeneron cuts White House pricing deal, offers new gene therapy for free | ||
| Fr | Cumberland to sell drug portfolio to Apotex for $100m | ||
| 23.04. | 500,000 patients' data for sale online after UK Biobank breach | ||
| 23.04. | Sanofi receives FDA approval for Tzield in paediatric diabetes | ||
| 23.04. | AbbVie opts for North Carolina to house $1.4bn manufacturing site | ||
| 23.04. | MSD teams up with Google Cloud on agentic AI transformation | ||
| 22.04. | Medicare weight loss drug pilot on ice as insurers decline to contribute | ||
| 22.04. | MSD-backed Ray locks in $125m to back eye drug pipeline | ||
| 22.04. | FDA approves MSD's once-daily HIV combo Idvynso | ||
| 22.04. | BioAegis and Prenosis partner for inflammatory disease therapies |